Receive The Newest Study Notifications

Galectin Therapeutics’ Phase 2 NASH Cirrhosis Clinical Trial Results on Belapectin (GR-MD-02) Published in Gastroenterology

by Lance Smith | Dec 9, 2019 | Study Scavenger Clinical Trial Recruitment Platform

NORCROSS, Ga., Dec. 09, 2019 (GLOBE NEWSWIRE) — Galectin Therapeutics Inc.(NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that a paper highlighting the results of its NASH-CX Phase 2 clinical trial in NASH...

Lilly Presents Interim Clinical Data from LOXO-305 Dose Escalation Trial in B-Cell Leukemias and Lymphomas at the American Society Hematology Annual Meeting

by Lance Smith | Dec 9, 2019 | Study Scavenger Clinical Trial Recruitment Platform

Responses observed at all dose levels in Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL), including patients with BTK Resistance, BTK Intolerance, and BCL2 Resistance INDIANAPOLIS, Dec. 8, 2019 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY)...

Aprea Therapeutics Presents Results From U.S. Phase Ib/II Clinical Trial of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) at the 2019 American Society of Hematology (ASH) Annual Meeting in Orlando

by Lance Smith | Dec 9, 2019 | Study Scavenger Clinical Trial Recruitment Platform

88% ORR, 61% CR rate by IWG criteria in 33 evaluable MDS patients 8.4 months median duration of response, with 7.3 months median duration of CR in evaluable MDS patients 52% of evaluable MDS patients discontinued treatment for stem cell transplant BOSTON, Dec. 09,...

KalVista Pharmaceuticals Reports Phase 2 Clinical Trial Results in Patients with Diabetic Macular Edema

by Lance Smith | Dec 9, 2019 | Study Scavenger Clinical Trial Recruitment Platform

– KVD001 Does Not Meet Primary Endpoint – – Pre-Planned Analyses Show Clinical Benefit on Vision – – KVD001 Generally Safe and Well Tolerated – KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery,...

Altasciences to Conduct Clinical Trial for Opioid Use Disorder Under NIH Funding

by Lance Smith | Dec 9, 2019 | Study Scavenger Clinical Trial Recruitment Platform

LAVAL, Quebec — Altasciences has been selected by Indivior PLC to conduct “A Phase I, Double-Blind, Placebo-Controlled, Randomized, Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of INDV-2000 (C4X_3256) Under Fasting and Fed...

ALX Oncology Presents Initial Data from the ALX148 Clinical Trial Non-Hodgkin Lymphoma Combination Cohort at the 61st American Society of Hematology (ASH)

by Lance Smith | Dec 9, 2019 | Study Scavenger Clinical Trial Recruitment Platform

DUBLIN, Ireland & BURLINGAME, Calif.–(BUSINESS WIRE)–ALX Oncology, a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint mechanism, today announced new results from the hematological portion of the ALX148 Phase 1...